Overview

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Status:
RECRUITING

Trial end date:
2028-12-15

Target enrollment:

Participant gender:

Summary

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).

Phase:

PHASE3

Details

Lead Sponsor:

OSE Immunotherapeutics

Collaborators:

Exystat
Genome Diagnostics (GenDx)

Treatments:

Docetaxel